Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1).

Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S, Noah DL.

Life Sci. 2012 Mar 10;90(11-12):440-5. doi: 10.1016/j.lfs.2011.12.014. Epub 2012 Jan 16.

2.
3.

Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors.

Sidwell RW, Wong MH, Bailey KW, Barnard DL, Jackson MK, Smee DF.

Antivir Chem Chemother. 2001 Nov;12(6):359-65.

PMID:
12018681
4.

The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.

Tanaka A, Nakamura S, Seki M, Iwanaga N, Kajihara T, Kitano M, Homma T, Kurihara S, Imamura Y, Miyazaki T, Izumikawa K, Kakeya H, Yanagihara K, Kohno S.

Antivir Ther. 2015;20(1):11-9. doi: 10.3851/IMP2744. Epub 2014 Feb 12.

PMID:
24517996
5.

The immuno-regulatory impact of orally-administered Hypericum perforatum extract on Balb/C mice inoculated with H1n1 influenza A virus.

Huang N, Singh N, Yoon K, Loiacono CM, Kohut ML, Birt DF.

PLoS One. 2013 Sep 30;8(9):e76491. doi: 10.1371/journal.pone.0076491. eCollection 2013.

6.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C.

Antiviral Res. 2016 Mar;127:68-78. doi: 10.1016/j.antiviral.2016.01.011. Epub 2016 Jan 21.

PMID:
26802558
7.

In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009.

Rowe T, Banner D, Farooqui A, Ng DC, Kelvin AA, Rubino S, Huang SS, Fang Y, Kelvin DJ.

J Gen Virol. 2010 Dec;91(Pt 12):2898-906. doi: 10.1099/vir.0.024323-0. Epub 2010 Aug 25.

PMID:
20797971
8.

Impaired wound healing predisposes obese mice to severe influenza virus infection.

O'Brien KB, Vogel P, Duan S, Govorkova EA, Webby RJ, McCullers JA, Schultz-Cherry S.

J Infect Dis. 2012 Jan 15;205(2):252-61. doi: 10.1093/infdis/jir729. Epub 2011 Dec 5.

9.

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.

Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT.

PLoS One. 2012;7(1):e31006. doi: 10.1371/journal.pone.0031006. Epub 2012 Jan 23.

10.

Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.

Belser JA, Szretter KJ, Katz JM, Tumpey TM.

Virology. 2013 Apr 25;439(1):42-6. doi: 10.1016/j.virol.2013.01.017. Epub 2013 Mar 1.

11.

Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine.

Smee DF, Wandersee MK, Wong MH, Bailey KW, Sidwell RW.

Antivir Chem Chemother. 2004 Sep;15(5):261-8.

PMID:
15535048
12.

Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C.

Kim EH, Pascua PN, Song MS, Baek YH, Kwon HI, Park SJ, Lim GJ, Kim SM, Decano A, Lee KJ, Cho WK, Ma JY, Choi YK.

Antiviral Res. 2013 Jun;98(3):386-93. doi: 10.1016/j.antiviral.2013.04.006. Epub 2013 Apr 13.

PMID:
23588232
13.

Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.

Baz M, Abed Y, Nehmé B, Boivin G.

Antimicrob Agents Chemother. 2009 Feb;53(2):791-3. doi: 10.1128/AAC.01276-08. Epub 2008 Nov 17.

14.

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD.

Antimicrob Agents Chemother. 2009 May;53(5):2120-8. doi: 10.1128/AAC.01012-08. Epub 2009 Mar 9.

15.

Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.

Kitano M, Kodama M, Itoh Y, Kanazu T, Kobayashi M, Yoshida R, Sato A.

Antimicrob Agents Chemother. 2013 May;57(5):2286-94. doi: 10.1128/AAC.02324-12. Epub 2013 Mar 11.

16.

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.

Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT.

PLoS One. 2010 Feb 22;5(2):e9332. doi: 10.1371/journal.pone.0009332.

17.

Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.

Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Yoshinaga T, Naito A, Sato A.

Antiviral Res. 2015 May;117:52-9. doi: 10.1016/j.antiviral.2015.02.012. Epub 2015 Mar 6.

PMID:
25752738
18.

Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir.

Hong EH, Song JH, Shim A, Lee BR, Kwon BE, Song HH, Kim YJ, Chang SY, Jeong HG, Kim JG, Seo SU, Kim H, Kwon Y, Ko HJ.

PLoS One. 2015 Jun 22;10(6):e0131089. doi: 10.1371/journal.pone.0131089. eCollection 2015.

19.

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.

Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. doi: 10.1128/AAC.01579-07. Epub 2008 Aug 25.

20.

[In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].

Shishkina LN, Nebol'sin VE, Skarnovich MO, Kabanov AS, Sergeev AA, Erdyneeva UB, Serova OA, Demina OK, Agafonov AP, Stavskiĭ EA, Drozdov IG.

Antibiot Khimioter. 2010;55(5-6):32-5. Russian.

PMID:
21033472

Supplemental Content

Support Center